IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v27y2009i8p635-643.html
   My bibliography  Save this article

Estimating Drug Costs in Economic Evaluations in Ireland and the UK

Author

Listed:
  • Dyfrig Hughes
  • Lesley Tilson
  • Michael Drummond

Abstract

Cost estimates for the drug of interest, its comparator and concomitant drugs are an important component of pharmacoeconomic evaluations. However, whilst in general considerable efforts are made by analysts to ensure valid and accurate parameter inputs, the methods for estimating drug costs are often lacking. We reviewed recent pharmacoeconomic evaluations undertaken in Ireland and the UK and documented the sources of data for drug costs and the methods of cost estimation. Methods were often inadequately described and, where adequate information was available, there was considerable variation and limitations in the methods used, thereby reducing the comparability of studies. Data from a sample of studies from other Northern European countries suggested that the findings from Ireland and the UK were not atypical. In order to improve current practice we suggest a methodological checklist for use in future studies. Copyright Adis Data Information BV 2009

Suggested Citation

  • Dyfrig Hughes & Lesley Tilson & Michael Drummond, 2009. "Estimating Drug Costs in Economic Evaluations in Ireland and the UK," PharmacoEconomics, Springer, vol. 27(8), pages 635-643, August.
    • Handle: RePEc:spr:pharme:v:27:y:2009:i:8:p:635-643
    DOI: 10.2165/10899570-000000000-00000
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.2165/10899570-000000000-00000
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.2165/10899570-000000000-00000?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Leivo, T. & Salomaa, A. & Kosunen, T. U. & Tuominen, R. & Farkkila, M. & Linna, M. & Sintonen, H., 2004. "Cost-benefit analysis of Helicobacter pylori screening," Health Policy, Elsevier, vol. 70(1), pages 85-96, October.
    2. Michael Barry & Lesley Tilson & Máirín Ryan, 2004. "Pricing and reimbursement of drugs in Ireland," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 5(2), pages 190-194, May.
    3. Martin Hoyle, 2008. "Future Drug Prices and Cost-Effectiveness Analyses," PharmacoEconomics, Springer, vol. 26(7), pages 589-602, July.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Martin Hoyle, 2011. "Accounting for the Drug Life Cycle and Future Drug Prices in Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 29(1), pages 1-15, January.
    2. Anke Richter, 2008. "Assessing the Impact of Global Price Interdependencies," PharmacoEconomics, Springer, vol. 26(8), pages 649-659, August.
    3. Paul Gorecki, 2011. "Do you believe in magic? Improving the quality of pharmacy services through restricting entry and aspirational contracts, the Irish experience," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(6), pages 521-531, December.
    4. Refoios Camejo, Rodrigo & McGrath, Clare & Herings, Ron, 2011. "A dynamic perspective on pharmaceutical competition, drug development and cost effectiveness," Health Policy, Elsevier, vol. 100(1), pages 18-24, April.
    5. Gorecki, Paul K. & Nolan, Anne & Brick, Aoife & Lyons, Seán, 2012. "Pharmaceuticals Delivery in Ireland. Getting a Bigger Bang for the Buck," Research Series, Economic and Social Research Institute (ESRI), number RS24.
    6. Lesley Tilson & Kathleen Bennett & Michael Barry, 2005. "The potential impact of implementing a system of generic substitution on the community drug schemes in Ireland," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(3), pages 267-273, September.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:27:y:2009:i:8:p:635-643. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.